SCHEMBL337027

SCHEMBL337027

COC(=O)c1c(O)c2cc(N3CCCCC3)nnc2n(C)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.39
▸ KDM4E B2RXH2 6/20 0.34
▸ NPC1 O15118 4/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ MAPT P10636 5/20 0.34
▸ TP53 P04637 2/20 0.34
▸ POLB P06746 2/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ ALOX12 P18054 1/20 0.33
▸ CNR2 P34972 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ PPARG P37231 1/20 0.33
▸ NCOA2 Q15596 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ PKM P14618 1/20 0.33
▸ KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336475 0.82 EGLN1 (0.49) —
SCHEMBL337571 0.80 CALCA (0.41) KDM4E
SCHEMBL336185 0.78 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTHPGDCNR2
SCHEMBL336867 0.78 ALDH1A1 (0.41) ALDH1A1KDM4ENPC1RAB9ANPSR1
SCHEMBL2434416 0.70 ALDH1A1 (0.44) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2577076 0.67 ALDH1A1 (0.40) ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL2579380 0.67 ALDH1A1 (0.45) ALDH1A1KDM4EHPGD
SCHEMBL2578302 0.67 CNR2 (0.46) ALDH1A1KDM4ESMN1; SMN2MAPTCNR2
SCHEMBL10080871 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ENPC1SMN1; SMN2MAPT
SCHEMBL2580133 0.65 EGLN1 (0.53) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097620-B2 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2012-01-17 — — US disclosed
EP-2155746-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY Amgen, Inc (US) 2010-02-24 — — EP disclosed
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity AMGEN INC. (US) 2009-04-16 — — US disclosed
WO-2008137084-A2 DIAZAQUINOLONES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY AMGEN INC. (US) 2008-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099171-A1 Diazaquinolones that inhibit prolyl hydroxylase activity EGLN3, EGLN2, HIF1AN ALDH1A1 108/4885KDM4E 248/4885NPC1 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback